International Heart Journal
Online ISSN : 1349-3299
Print ISSN : 1349-2365
ISSN-L : 1349-2365
Case Reports
Correction of Hyponatremia by Tolvaptan Before Left Ventricular Assist Device Implantation
Teruhiko ImamuraKoichiro KinugawaTaro ShigaNaoko KatoMiyoko EndoToshiro InabaHisataka MakiMasaru HatanoAtsushi YaoYasunobu HirataTakashi NishimuraShunei KyoMinoru OnoRyozo Nagai
Author information
JOURNAL FREE ACCESS

2012 Volume 53 Issue 6 Pages 391-393

Details
Abstract

Hypervolemic hyponatremia is often complicated with advanced heart failure together with increased excretion of sodium by diuretics. Tolvaptan, an oral vasopressin-2-receptor antagonist, has been previously reported to improve congestion and correct hyponatremia through increased excretion of free water. However, there is little evidence concerning the administration of tolvaptan in patients with stage D heart failure. We experienced 2 patients with stage D heart failure who received 3.75 mg/day of tolvaptan to correct hyponatremia before ventricular assist device implantation. It may be useful, even for patients with stage D heart failure, to administer a low dose of tolvaptan to treat hyponatremia before ventricular assist device implantation to avoid a drastic alteration in serum sodium concentration perioperatively.

Content from these authors
© 2012 by the International Heart Journal Association
Previous article Next article
feedback
Top